Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to identify treated PAH patients using population-based health administrative databases. We investigated demographic and clinical characteristics of treated PAH patients and conducted a cohort study to determine treatment patterns, healthcare utilization, and associated costs, over a one-year follow-up period (March 2012). Results. We identified 326 treated PAH cases in Ontario's publicly funded drug plan. Overall mean age was 59.4 years (±20.3 years) and over 77% of cases were women (n = 251). Combination therapy was used to treat 22.9% (n = 69) of cases, costing an average of $4,569 (SD $1,544) per month. Median monthly healthcare costs were $264 (IQR $96-$747) for those who survived and $2,021 (IQR $993-$6,399) for those who died over a one-year period, respectively (p < 0.01). Conclusions. PAH care in Ontario is complex and has high healthcare costs. This data may help guide towards improved patient management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904539 | PMC |
| http://dx.doi.org/10.1155/2016/6279250 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NSD2 mediated H3K36me2 promotes pulmonary arterial hypertension by recruiting FOLR1 and metabolism reprogramming.
Cell Signal
January 2025
Department of Cardiovascular Surgery, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Electronic address:
Article Synopsis
- Pulmonary artery hypertension (PAH) exhibits a metabolic shift towards aerobic glycolysis, resembling cancer metabolism, and involves the role of NSD2, though its exact function is not fully understood.
- Increased expression of FOLR1 in PAH tissues was linked to NSD2, and silencing either NSD2 or FOLR1 inhibited cell proliferation and the progression of PAH.
- The study found that NSD2 influences the activity of FOLR1, affecting glycolytic gene expression and metabolic processes in pulmonary artery endothelial cells, suggesting a potential pathway for therapeutic intervention in PAH.
Protocol for applying Tumor Treating Fields in mouse models of cancer using the inovivo system.
STAR Protoc
January 2025
Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA; Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, MN, USA. Electronic address:
Tumor Treating Fields (TTFields) are electric fields clinically approved for cancer treatment, delivered via arrays attached to the patient's skin. Here, we present a protocol for applying TTFields to torso orthotopic and subcutaneous mouse tumor models using the inovivo system. We guide users on proper system component connections, study protocol design, mouse fur depilation, array application, and treatment condition adjustment and monitoring.
View Article and Find Full Text PDFBiochar in the Remediation of Organic Pollutants in Water: A Review of Polycyclic Aromatic Hydrocarbon and Pesticide Removal.
Nanomaterials (Basel)
December 2024
Faculty of Sciences, University of Novi Sad, 21000 Novi Sad, Serbia.
This review explores biochar's potential as a sustainable and cost-effective solution for remediating organic pollutants, particularly polycyclic aromatic hydrocarbons (PAHs) and pesticides, in water. Biochar, a carbon-rich material produced from biomass pyrolysis, has demonstrated adsorption efficiencies exceeding 90% under optimal conditions, depending on the feedstock type, pyrolysis temperature, and functionalization. High surface area (up to 1500 m/g), porosity, and modifiable surface functional groups make biochar effective in adsorbing a wide range of contaminants, including toxic metals, organic pollutants, and nutrients.
View Article and Find Full Text PDFThe Prognostic Value of Right Ventricular End-Diastolic Basal Diameter Index by Echocardiography in Connective Tissue Diseases Associated With Pulmonary Artery Hypertension.
Int J Rheum Dis
January 2025
Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: Right ventricular (RV) failure is a well-recognized pivotal prognostic factor of adverse outcomes in pulmonary artery hypertension (PAH), while RV dilation provides significant implications for adaptive or maladaptive changes. PAH is a predominant cause of mortality among patients with connective tissue disease (CTD). This study aims to elucidate the prognostic significance of RV morphology, as assessed by echocardiography (ECHO), in with CTD associated with PAH (CTD-PAH).
View Article and Find Full Text PDFA simple HPLC-UV method for monitoring therapeutic adherence in pulmonary arterial hypertension.
J Chromatogr B Analyt Technol Biomed Life Sci
December 2024
Pulmonary Circulation Centre, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Krakow, Poland; Department of Cardiac and Vascular Diseases, St. John Paul II Hospital, Krakow, Poland.
A considerable percentage of ineffective treatment in pulmonary arterial hypertension (PAH) may be related to subtherapeutic dosage or non-adherence. The aim of the study was to develop a simple analytical method suitable for plasma determination of selected drugs: riociguat (RIO), bosentan (BOS) and macitentan (MAC) administered to PAH patients. An isocratic HPLC-UV system (Spectra Physics - Shimadzu) with a manual injector (50 μL loop) was applied.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!